Heteromeric Amino Acid Transporters in Brain: from Physiology to Pathology.
Amino acid transporter
CNS
Disease
HAT
LAT
SLC7
Journal
Neurochemical research
ISSN: 1573-6903
Titre abrégé: Neurochem Res
Pays: United States
ID NLM: 7613461
Informations de publication
Date de publication:
Jan 2022
Jan 2022
Historique:
received:
02
11
2020
accepted:
30
01
2021
revised:
27
01
2021
pubmed:
20
2
2021
medline:
1
4
2022
entrez:
19
2
2021
Statut:
ppublish
Résumé
In humans, more than 50 transporters are responsible for the traffic and balance of amino acids within and between cells and tissues, and half of them have been associated with disease [1]. Covering all common amino acids, Heteromeric Amino acid Transporters (HATs) are one class of such transporters. This review first highlights structural and functional studies that solved the atomic structure of HATs and revealed molecular clues on substrate interaction. Moreover, this review focuses on HATs that have a role in the central nervous system (CNS) and that are related to neurological diseases, including: (i) LAT1/CD98hc and its role in the uptake of branched chain amino acids trough the blood brain barrier and autism. (ii) LAT2/CD98hc and its potential role in the transport of glutamine between plasma and cerebrospinal fluid. (iii) y
Identifiants
pubmed: 33606172
doi: 10.1007/s11064-021-03261-w
pii: 10.1007/s11064-021-03261-w
doi:
Substances chimiques
Amino Acid Transport Systems
0
Amino Acids
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
23-36Informations de copyright
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC part of Springer Nature.
Références
Bröer S, Palacín M (2011) The role of amino acid transporters in inherited and acquired diseases. Biochem J 436(2):193–211. https://doi.org/10.1042/BJ20101912
doi: 10.1042/BJ20101912
pubmed: 21568940
Fotiadis D, Kanai Y, Palacín M (2013) The SLC3 and SLC7 families of amino acid transporters. Mol Aspects Med 34(2–3):139–158. https://doi.org/10.1016/j.mam.2012.10.007
doi: 10.1016/j.mam.2012.10.007
pubmed: 23506863
Closs EI, Boissel JP, Habermeier A, Rotmann A (2006) Structure and function of cationic amino acid transporters (CATs). J Membr Biol 213(2):67–77. https://doi.org/10.1007/s00232-006-0875-7
doi: 10.1007/s00232-006-0875-7
pubmed: 17417706
Fukasawa Y, Segawa H, Kim JY, Chairoungdua A, Kim DK, Matsuo H, Cha SH, Endou H, Kanai Y (2000) Identification and characterization of a Na(+)-independent neutral amino acid transporter that associates with the 4F2 heavy chain and exhibits substrate selectivity for small neutral D- and L-amino acids. J Biol Chem 275(13):9690–9698. https://doi.org/10.1074/jbc.275.13.9690
doi: 10.1074/jbc.275.13.9690
pubmed: 10734121
Mastroberardino L, Spindler B, Pfeiffer R, Skelly PJ, Loffing J, Shoemaker CB, Verrey F (1998) Amino-acid transport by heterodimers of 4F2hc/CD98 and members of a permease family. Nature 395(6699):288–291. https://doi.org/10.1038/26246
doi: 10.1038/26246
pubmed: 9751058
Pfeiffer R, Rossier G, Spindler B, Meier C, Kühn L, Verrey F (1999) Amino acid transport of y+L-type by heterodimers of 4F2hc/CD98 and members of the glycoprotein-associated amino acid transporter family. EMBO J 18(1):49–57. https://doi.org/10.1093/emboj/18.1.49
doi: 10.1093/emboj/18.1.49
pubmed: 9878049
pmcid: 1171101
Pineda M, Fernández E, Torrents D, Estévez R, López C, Camps M, Lloberas J, Zorzano A, Palacín M (1999) Identification of a membrane protein, LAT-2, that Co-expresses with 4F2 heavy chain, an L-type amino acid transport activity with broad specificity for small and large zwitterionic amino acids. J Biol Chem 274(28):19738–19744. https://doi.org/10.1074/jbc.274.28.19738
doi: 10.1074/jbc.274.28.19738
pubmed: 10391915
Sato H, Tamba M, Ishii T, Bannai S (1999) Cloning and expression of a plasma membrane cystine/glutamate exchange transporter composed of two distinct proteins. J Biol Chem 274(17):11455–11458. https://doi.org/10.1074/jbc.274.17.11455
doi: 10.1074/jbc.274.17.11455
pubmed: 10206947
Torrents D, Estévez R, Pineda M, Fernández E, Lloberas J, Shi YB, Zorzano A, Palacín M (1998) Identification and characterization of a membrane protein (y+L amino acid transporter-1) that associates with 4F2hc to encode the amino acid transport activity y+L. A candidate gene for lysinuric protein intolerance. J Biol Chem 273 (49):32437–32445. doi: https://doi.org/10.1074/jbc.273.49.32437
Feliubadaló L, Font M, Purroy J, Rousaud F, Estivill X, Nunes V, Golomb E, Centola M, Aksentijevich I, Kreiss Y, Goldman B, Pras M, Kastner DL, Pras E, Gasparini P, Bisceglia L, Beccia E, Gallucci M, de Sanctis L, Ponzone A, Rizzoni GF, Zelante L, Bassi MT, George AL, Manzoni M, De Grandi A, Riboni M, Endsley JK, Ballabio A, Borsani G, Reig N, Fernández E, Estévez R, Pineda M, Torrents D, Camps M, Lloberas J, Zorzano A, Palacín M (1999) Non-type I cystinuria caused by mutations in SLC7A9, encoding a subunit (bo,+AT) of rBAT. Nat Genet 23(1):52–57. https://doi.org/10.1038/12652
doi: 10.1038/12652
pubmed: 10471498
Nagamori S, Wiriyasermkul P, Guarch ME, Okuyama H, Nakagomi S, Tadagaki K, Nishinaka Y, Bodoy S, Takafuji K, Okuda S, Kurokawa J, Ohgaki R, Nunes V, Palacín M, Kanai Y (2016) Novel cystine transporter in renal proximal tubule identified as a missing partner of cystinuria-related plasma membrane protein rBAT/SLC3A1. Proc Natl Acad Sci U S A 113(3):775–780. https://doi.org/10.1073/pnas.1519959113
doi: 10.1073/pnas.1519959113
pubmed: 26739563
pmcid: 4725474
Calonge MJ, Gasparini P, Chillarón J, Chillón M, Gallucci M, Rousaud F, Zelante L, Testar X, Dallapiccola B, Di Silverio F (1994) Cystinuria caused by mutations in rBAT, a gene involved in the transport of cystine. Nat Genet 6(4):420–425. https://doi.org/10.1038/ng0494-420
doi: 10.1038/ng0494-420
pubmed: 8054986
Torrents D, Mykkänen J, Pineda M, Feliubadaló L, Estévez R, de Cid R, Sanjurjo P, Zorzano A, Nunes V, Huoponen K, Reinikainen A, Simell O, Savontaus ML, Aula P, Palacín M (1999) Identification of SLC7A7, encoding y+LAT-1, as the lysinuric protein intolerance gene. Nat Genet 21(3):293–296. https://doi.org/10.1038/6809
doi: 10.1038/6809
pubmed: 10080182
Espino Guarch M, Font-Llitjós M, Murillo-Cuesta S, Errasti-Murugarren E, Celaya AM, Girotto G, Vuckovic D, Mezzavilla M, Vilches C, Bodoy S, Sahún I, González L, Prat E, Zorzano A, Dierssen M, Varela-Nieto I, Gasparini P, Palacín M, Nunes V (2018) Mutations in L-type amino acid transporter-2 support SLC7A8 as a novel gene involved in age-related hearing loss. Elife. https://doi.org/10.7554/eLife.31511
doi: 10.7554/eLife.31511
pubmed: 29355479
pmcid: 5811215
Knöpfel EB, Vilches C, Camargo SMR, Errasti-Murugarren E, Stäubli A, Mayayo C, Munier FL, Miroshnikova N, Poncet N, Junza A, Bhattacharya SS, Prat E, Berry V, Berger W, Heon E, Moore AT, Yanes Ó, Nunes V, Palacín M, Verrey F, Kloeckener-Gruissem B (2019) Dysfunctional LAT2 amino acid transporter Is associated with cataract in mouse and humans. Front Physiol 10:688. https://doi.org/10.3389/fphys.2019.00688
doi: 10.3389/fphys.2019.00688
pubmed: 31231240
pmcid: 6558864
Tărlungeanu DC, Deliu E, Dotter CP, Kara M, Janiesch PC, Scalise M, Galluccio M, Tesulov M, Morelli E, Sonmez FM, Bilguvar K, Ohgaki R, Kanai Y, Johansen A, Esharif S, Ben-Omran T, Topcu M, Schlessinger A, Indiveri C, Duncan KE, Caglayan AO, Gunel M, Gleeson JG, Novarino G (2016) Impaired amino acid transport at the blood brain barrier Is a cause of autism spectrum disorder. Cell 167(6):1481-1494.e1418. https://doi.org/10.1016/j.cell.2016.11.013
doi: 10.1016/j.cell.2016.11.013
pubmed: 27912058
pmcid: 5554935
Veettil MV, Sadagopan S, Sharma-Walia N, Wang FZ, Raghu H, Varga L, Chandran B (2008) Kaposi’s sarcoma-associated herpesvirus forms a multimolecular complex of integrins (alphaVbeta5, alphaVbeta3, and alpha3beta1) and CD98-xCT during infection of human dermal microvascular endothelial cells, and CD98-xCT is essential for the postentry stage of infection. J Virol 82(24):12126–12144. https://doi.org/10.1128/JVI.01146-08
doi: 10.1128/JVI.01146-08
pubmed: 18829766
pmcid: 2593334
Baker DA, McFarland K, Lake RW, Shen H, Tang XC, Toda S, Kalivas PW (2003) Neuroadaptations in cystine-glutamate exchange underlie cocaine relapse. Nat Neurosci 6(7):743–749. https://doi.org/10.1038/nn1069
doi: 10.1038/nn1069
pubmed: 12778052
Fan X, Ross DD, Arakawa H, Ganapathy V, Tamai I, Nakanishi T (2010) Impact of system L amino acid transporter 1 (LAT1) on proliferation of human ovarian cancer cells: a possible target for combination therapy with anti-proliferative aminopeptidase inhibitors. Biochem Pharmacol 80(6):811–818. https://doi.org/10.1016/j.bcp.2010.05.021
doi: 10.1016/j.bcp.2010.05.021
pubmed: 20510678
Lo M, Wang YZ, Gout PW (2008) The x(c)- cystine/glutamate antiporter: a potential target for therapy of cancer and other diseases. J Cell Physiol 215(3):593–602. https://doi.org/10.1002/jcp.21366
doi: 10.1002/jcp.21366
pubmed: 18181196
Bröer A, Rahimi F, Bröer S (2016) Deletion of amino acid transporter ASCT2 (SLC1A5) reveals an essential role for transporters SNAT1 (SLC38A1) and SNAT2 (SLC38A2) to sustain glutaminolysis in cancer cells. J Biol Chem 291(25):13194–13205. https://doi.org/10.1074/jbc.M115.700534
doi: 10.1074/jbc.M115.700534
pubmed: 27129276
pmcid: 4933233
Nicklin P, Bergman P, Zhang B, Triantafellow E, Wang H, Nyfeler B, Yang H, Hild M, Kung C, Wilson C, Myer VE, MacKeigan JP, Porter JA, Wang YK, Cantley LC, Finan PM, Murphy LO (2009) Bidirectional transport of amino acids regulates mTOR and autophagy. Cell 136(3):521–534. https://doi.org/10.1016/j.cell.2008.11.044
doi: 10.1016/j.cell.2008.11.044
pubmed: 19203585
pmcid: 3733119
Vilches C, Boiadjieva-Knöpfel E, Bodoy S, Camargo S, López de Heredia M, Prat E, Ormazabal A, Artuch R, Zorzano A, Verrey F, Nunes V, Palacín M (2018) Cooperation of antiporter LAT2/CD98hc with uniporter TAT1 for renal reabsorption of neutral amino acids. J Am Soc Nephrol 29(6):1624–1635. https://doi.org/10.1681/ASN.2017111205
doi: 10.1681/ASN.2017111205
pubmed: 29610403
pmcid: 6054336
Lee Y, Wiriyasermkul P, Jin C, Quan L, Ohgaki R, Okuda S, Kusakizako T, Nishizawa T, Oda K, Ishitani R, Yokoyama T, Nakane T, Shirouzu M, Endou H, Nagamori S, Kanai Y, Nureki O (2019) Cryo-EM structure of the human L-type amino acid transporter 1 in complex with glycoprotein CD98hc. Nat Struct Mol Biol 26(6):510–517. https://doi.org/10.1038/s41594-019-0237-7
doi: 10.1038/s41594-019-0237-7
pubmed: 31160781
Wu D, Grund TN, Welsch S, Mills DJ, Michel M, Safarian S, Michel H (2020) Structural basis for amino acid exchange by a human heteromeric amino acid transporter. Proc Natl Acad Sci U S A 117(35):21281–21287. https://doi.org/10.1073/pnas.2008111117
doi: 10.1073/pnas.2008111117
pubmed: 32817565
pmcid: 7474693
Yan R, Li Y, Shi Y, Zhou J, Lei J, Huang J, Zhou Q (2020) Cryo-EM structure of the human heteromeric amino acid transporter b0,+AT-rBAT. Sci Adv 6 (16):eaay6379. doi: https://doi.org/10.1126/sciadv.aay6379
Yan R, Zhao X, Lei J, Zhou Q (2019) Structure of the human LAT1-4F2hc heteromeric amino acid transporter complex. Nature 568(7750):127–130. https://doi.org/10.1038/s41586-019-1011-z
doi: 10.1038/s41586-019-1011-z
pubmed: 30867591
Errasti-Murugarren E, Fort J, Bartoccioni P, Díaz L, Pardon E, Carpena X, Espino-Guarch M, Zorzano A, Ziegler C, Steyaert J, Fernández-Recio J, Fita I, Palacín M (2019) L amino acid transporter structure and molecular bases for the asymmetry of substrate interaction. Nat Commun 10(1):1807. https://doi.org/10.1038/s41467-019-09837-z
doi: 10.1038/s41467-019-09837-z
pubmed: 31000719
pmcid: 6472337
Jungnickel KEJ, Parker JL, Newstead S (2018) Structural basis for amino acid transport by the CAT family of SLC7 transporters. Nat Commun 9(1):550. https://doi.org/10.1038/s41467-018-03066-6
doi: 10.1038/s41467-018-03066-6
pubmed: 29416041
pmcid: 5803215
Meier C, Ristic Z, Klauser S, Verrey F (2002) Activation of system L heterodimeric amino acid exchangers by intracellular substrates. EMBO J 21(4):580–589. https://doi.org/10.1093/emboj/21.4.580
doi: 10.1093/emboj/21.4.580
pubmed: 11847106
pmcid: 125871
Reig N, Chillarón J, Bartoccioni P, Fernández E, Bendahan A, Zorzano A, Kanner B, Palacín M, Bertran J (2002) The light subunit of system b(o,+) is fully functional in the absence of the heavy subunit. EMBO J 21(18):4906–4914. https://doi.org/10.1093/emboj/cdf500
doi: 10.1093/emboj/cdf500
pubmed: 12234930
pmcid: 126296
Sperandeo MP, Annunziata P, Ammendola V, Fiorito V, Pepe A, Soldovieri MV, Taglialatela M, Andria G, Sebastio G (2005) Lysinuric protein intolerance: identification and functional analysis of mutations of the SLC7A7 gene. Hum Mutat 25(4):410. https://doi.org/10.1002/humu.9323
doi: 10.1002/humu.9323
pubmed: 15776427
Fang Y, Jayaram H, Shane T, Kolmakova-Partensky L, Wu F, Williams C, Xiong Y, Miller C (2009) Structure of a prokaryotic virtual proton pump at 3.2 A resolution. Nature 460 (7258):1040–1043. doi: https://doi.org/10.1038/nature08201
Gao X, Zhou L, Jiao X, Lu F, Yan C, Zeng X, Wang J, Shi Y (2010) Mechanism of substrate recognition and transport by an amino acid antiporter. Nature 463(7282):828–832. https://doi.org/10.1038/nature08741
doi: 10.1038/nature08741
pubmed: 20090677
Ilgü H, Jeckelmann JM, Gapsys V, Ucurum Z, de Groot BL, Fotiadis D (2016) Insights into the molecular basis for substrate binding and specificity of the wild-type L-arginine/agmatine antiporter AdiC. Proc Natl Acad Sci U S A 113(37):10358–10363. https://doi.org/10.1073/pnas.1605442113
doi: 10.1073/pnas.1605442113
pubmed: 27582465
pmcid: 5027449
Kowalczyk L, Ratera M, Paladino A, Bartoccioni P, Errasti-Murugarren E, Valencia E, Portella G, Bial S, Zorzano A, Fita I, Orozco M, Carpena X, Vázquez-Ibar JL, Palacín M (2011) Molecular basis of substrate-induced permeation by an amino acid antiporter. Proc Natl Acad Sci U S A 108(10):3935–3940. https://doi.org/10.1073/pnas.1018081108
doi: 10.1073/pnas.1018081108
pubmed: 21368142
pmcid: 3054010
Shaffer PL, Goehring A, Shankaranarayanan A, Gouaux E (2009) Structure and mechanism of a Na+-independent amino acid transporter. Science 325(5943):1010–1014. https://doi.org/10.1126/science.1176088
doi: 10.1126/science.1176088
pubmed: 19608859
pmcid: 2851542
Singh N, Ecker GF (2018) Insights into the structure, function, and ligand discovery of the Large neutral Amino acid Transporter 1, LAT1. Int J Mol Sci. https://doi.org/10.3390/ijms19051278
doi: 10.3390/ijms19051278
pubmed: 30577601
pmcid: 6337383
Torrecillas IR, Conde-Ceide S, de Lucas AI, Garcı A, Molina A, Trabanco AA, Lavreysen H, Pardo L, Tresadern G (2019) Inhibition of the alanine-serine-cysteine-1 transporter by BMS-466442. ACS Chem Neurosci 10(5):2510–2517. https://doi.org/10.1021/acschemneuro.9b00019
doi: 10.1021/acschemneuro.9b00019
pubmed: 30821959
Fort J, de la Ballina LR, Burghardt HE, Ferrer-Costa C, Turnay J, Ferrer-Orta C, Usón I, Zorzano A, Fernández-Recio J, Orozco M, Lizarbe MA, Fita I, Palacín M (2007) The structure of human 4F2hc ectodomain provides a model for homodimerization and electrostatic interaction with plasma membrane. J Biol Chem 282(43):31444–31452. https://doi.org/10.1074/jbc.M704524200
doi: 10.1074/jbc.M704524200
pubmed: 17724034
Fernández E, Jiménez-Vidal M, Calvo M, Zorzano A, Tebar F, Palacín M, Chillarón J (2006) The structural and functional units of heteromeric amino acid transporters. The heavy subunit rBAT dictates oligomerization of the heteromeric amino acid transporters. J Biol Chem 281(36):26552–26561. https://doi.org/10.1074/jbc.M604049200
doi: 10.1074/jbc.M604049200
pubmed: 16825196
Rosell A, Meury M, Álvarez-Marimon E, Costa M, Pérez-Cano L, Zorzano A, Fernández-Recio J, Palacín M, Fotiadis D (2014) Structural bases for the interaction and stabilization of the human amino acid transporter LAT2 with its ancillary protein 4F2hc. Proc Natl Acad Sci U S A 111(8):2966–2971. https://doi.org/10.1073/pnas.1323779111
doi: 10.1073/pnas.1323779111
pubmed: 24516142
pmcid: 3939895
Bodoy S, Sotillo F, Espino-Guarch M, Sperandeo MP, Ormazabal A, Zorzano A, Sebastio G, Artuch R, Palacín M (2019) Inducible Slc7a7 knockout mouse model recapitulates lysinuric protein intolerance disease. Int J Mol Sci . https://doi.org/10.3390/ijms20215294
Palacín M, Bertran J, Chillarón J, Estévez R, Zorzano A (2004) Lysinuric protein intolerance: mechanisms of pathophysiology. Mol Genet Metab 81(Suppl 1):S27-37. https://doi.org/10.1016/j.ymgme.2003.11.015
doi: 10.1016/j.ymgme.2003.11.015
pubmed: 15050971
Kanai Y, Segawa H, Miyamoto K, Uchino H, Takeda E, Endou H (1998) Expression cloning and characterization of a transporter for large neutral amino acids activated by the heavy chain of 4F2 antigen (CD98). J Biol Chem 273(37):23629–23632. https://doi.org/10.1074/jbc.273.37.23629
doi: 10.1074/jbc.273.37.23629
pubmed: 9726963
Furuya M, Horiguchi J, Nakajima H, Kanai Y, Oyama T (2012) Correlation of L-type amino acid transporter 1 and CD98 expression with triple negative breast cancer prognosis. Cancer Sci 103(2):382–389. https://doi.org/10.1111/j.1349-7006.2011.02151.x
doi: 10.1111/j.1349-7006.2011.02151.x
pubmed: 22077314
Haining Z, Kawai N, Miyake K, Okada M, Okubo S, Zhang X, Fei Z, Tamiya T (2012) Relation of LAT1/4F2hc expression with pathological grade, proliferation and angiogenesis in human gliomas. BMC Clin Pathol 12:4. https://doi.org/10.1186/1472-6890-12-4
doi: 10.1186/1472-6890-12-4
pubmed: 22373026
pmcid: 3305678
Nawashiro H, Otani N, Shinomiya N, Fukui S, Ooigawa H, Shima K, Matsuo H, Kanai Y, Endou H (2006) L-type amino acid transporter 1 as a potential molecular target in human astrocytic tumors. Int J Cancer 119(3):484–492. https://doi.org/10.1002/ijc.21866
doi: 10.1002/ijc.21866
pubmed: 16496379
Wang Q, Holst J (2015) L-type amino acid transport and cancer: targeting the mTORC1 pathway to inhibit neoplasia. Am J Cancer Res 5(4):1281–1294
pubmed: 26101697
pmcid: 4473310
Yue M, Jiang J, Gao P, Liu H, Qing G (2017) Oncogenic MYC activates a feedforward regulatory loop promoting essential amino acid metabolism and tumorigenesis. Cell Rep 21(13):3819–3832. https://doi.org/10.1016/j.celrep.2017.12.002
doi: 10.1016/j.celrep.2017.12.002
pubmed: 29281830
Saxton RA, Sabatini DM (2017) mTOR signaling in growth, metabolism, and disease. Cell 169(2):361–371. https://doi.org/10.1016/j.cell.2017.03.035
doi: 10.1016/j.cell.2017.03.035
pubmed: 28388417
Chen R, Zou Y, Mao D, Sun D, Gao G, Shi J, Liu X, Zhu C, Yang M, Ye W, Hao Q, Li R, Yu L (2014) The general amino acid control pathway regulates mTOR and autophagy during serum/glutamine starvation. J Cell Biol 206(2):173–182. https://doi.org/10.1083/jcb.201403009
doi: 10.1083/jcb.201403009
pubmed: 25049270
pmcid: 4107793
Wang Q, Bailey CG, Ng C, Tiffen J, Thoeng A, Minhas V, Lehman ML, Hendy SC, Buchanan G, Nelson CC, Rasko JE, Holst J (2011) Androgen receptor and nutrient signaling pathways coordinate the demand for increased amino acid transport during prostate cancer progression. Cancer Res 71(24):7525–7536. https://doi.org/10.1158/0008-5472.CAN-11-1821
doi: 10.1158/0008-5472.CAN-11-1821
pubmed: 22007000
Elorza A, Soro-Arnáiz I, Meléndez-Rodríguez F, Rodríguez-Vaello V, Marsboom G, de Cárcer G, Acosta-Iborra B, Albacete-Albacete L, Ordóñez A, Serrano-Oviedo L, Giménez-Bachs JM, Vara-Vega A, Salinas A, Sánchez-Prieto R, Martín del Río R, Sánchez-Madrid F, Malumbres M, Landázuri MO, Aragonés J (2012) HIF2α acts as an mTORC1 activator through the amino acid carrier SLC7A5. Mol Cell 48(5):681–691. https://doi.org/10.1016/j.molcel.2012.09.017
doi: 10.1016/j.molcel.2012.09.017
pubmed: 23103253
Brand K (1981) Metabolism of 2-oxoacid analogues of leucine, valine and phenylalanine by heart muscle, brain and kidney of the rat. Biochim Biophys Acta 677(1):126–132. https://doi.org/10.1016/0304-4165(81)90153-7
doi: 10.1016/0304-4165(81)90153-7
pubmed: 7295786
Yudkoff M (2017) Interactions in the metabolism of glutamate and the branched-chain amino acids and ketoacids in the CNS. Neurochem Res 42(1):10–18. https://doi.org/10.1007/s11064-016-2057-z
doi: 10.1007/s11064-016-2057-z
pubmed: 27696119
García-Cazorla A, Oyarzabal A, Fort J, Robles C, Castejón E, Ruiz-Sala P, Bodoy S, Merinero B, Lopez-Sala A, Dopazo J, Nunes V, Ugarte M, Artuch R, Palacín M, Rodríguez-Pombo P, Alcaide P, Navarrete R, Sanz P, Font-Llitjós M, Vilaseca MA, Ormaizabal A, Pristoupilova A, Agulló SB (2014) Two novel mutations in the BCKDK (branched-chain keto-acid dehydrogenase kinase) gene are responsible for a neurobehavioral deficit in two pediatric unrelated patients. Hum Mutat 35(4):470–477. https://doi.org/10.1002/humu.22513
doi: 10.1002/humu.22513
pubmed: 24449431
Novarino G, El-Fishawy P, Kayserili H, Meguid NA, Scott EM, Schroth J, Silhavy JL, Kara M, Khalil RO, Ben-Omran T, Ercan-Sencicek AG, Hashish AF, Sanders SJ, Gupta AR, Hashem HS, Matern D, Gabriel S, Sweetman L, Rahimi Y, Harris RA, State MW, Gleeson JG (2012) Mutations in BCKD-kinase lead to a potentially treatable form of autism with epilepsy. Science 338(6105):394–397. https://doi.org/10.1126/science.1224631
doi: 10.1126/science.1224631
pubmed: 22956686
pmcid: 3704165
Boado RJ, Li JY, Nagaya M, Zhang C, Pardridge WM (1999) Selective expression of the large neutral amino acid transporter at the blood-brain barrier. Proc Natl Acad Sci U S A 96(21):12079–12084. https://doi.org/10.1073/pnas.96.21.12079
doi: 10.1073/pnas.96.21.12079
pubmed: 10518579
pmcid: 18415
Bauch C, Forster N, Loffing-Cueni D, Summa V, Verrey F (2003) Functional cooperation of epithelial heteromeric amino acid transporters expressed in madin-darby canine kidney cells. J Biol Chem 278(2):1316–1322. https://doi.org/10.1074/jbc.M210449200
doi: 10.1074/jbc.M210449200
pubmed: 12417581
del Amo EM, Urtti A, Yliperttula M (2008) Pharmacokinetic role of L-type amino acid transporters LAT1 and LAT2. Eur J Pharm Sci 35(3):161–174. https://doi.org/10.1016/j.ejps.2008.06.015
doi: 10.1016/j.ejps.2008.06.015
pubmed: 18656534
Kanai Y, Endou H (2001) Heterodimeric amino acid transporters: molecular biology and pathological and pharmacological relevance. Curr Drug Metab 2(4):339–354. https://doi.org/10.2174/1389200013338324
doi: 10.2174/1389200013338324
pubmed: 11766986
Rossier G, Meier C, Bauch C, Summa V, Sordat B, Verrey F, Kühn LC (1999) LAT2, a new basolateral 4F2hc/CD98-associated amino acid transporter of kidney and intestine. J Biol Chem 274(49):34948–34954. https://doi.org/10.1074/jbc.274.49.34948
doi: 10.1074/jbc.274.49.34948
pubmed: 10574970
Widdows KL, Panitchob N, Crocker IP, Please CP, Hanson MA, Sibley CP, Johnstone ED, Sengers BG, Lewis RM, Glazier JD (2015) Integration of computational modeling with membrane transport studies reveals new insights into amino acid exchange transport mechanisms. FASEB J 29(6):2583–2594. https://doi.org/10.1096/fj.14-267773
doi: 10.1096/fj.14-267773
pubmed: 25761365
pmcid: 4469330
Gaccioli F, Aye IL, Roos S, Lager S, Ramirez VI, Kanai Y, Powell TL, Jansson T (2015) Expression and functional characterisation of System L amino acid transporters in the human term placenta. Reprod Biol Endocrinol 13:57. https://doi.org/10.1186/s12958-015-0054-8
doi: 10.1186/s12958-015-0054-8
pubmed: 26050671
pmcid: 4462079
Braun D, Wirth EK, Wohlgemuth F, Reix N, Klein MO, Grüters A, Köhrle J, Schweizer U (2011) Aminoaciduria, but normal thyroid hormone levels and signalling, in mice lacking the amino acid and thyroid hormone transporter Slc7a8. Biochem J 439(2):249–255. https://doi.org/10.1042/BJ20110759
doi: 10.1042/BJ20110759
pubmed: 21726201
Dolgodilina E, Camargo SM, Roth E, Herzog B, Nunes V, Palacín M, Verrey F (2020) Choroid plexus LAT2 and SNAT3 as partners in CSF amino acid homeostasis maintenance. Fluids Barriers CNS 17(1):17. https://doi.org/10.1186/s12987-020-0178-x
doi: 10.1186/s12987-020-0178-x
pubmed: 32046769
pmcid: 7014681
Cascio L, Chen CF, Pauly R, Srikanth S, Jones K, Skinner CD, Stevenson RE, Schwartz CE, Boccuto L (2020) Abnormalities in the genes that encode large amino acid transporters increase the risk of autism spectrum disorder. Mol Genet Genomic Med 8(1):e1036. https://doi.org/10.1002/mgg3.1036
doi: 10.1002/mgg3.1036
pubmed: 31701662
McGale EH, Pye IF, Stonier C, Hutchinson EC, Aber GM (1977) Studies of the inter-relationship between cerebrospinal fluid and plasma amino acid concentrations in normal individuals. J Neurochem 29(2):291–297. https://doi.org/10.1111/j.1471-4159.1977.tb09621.x
doi: 10.1111/j.1471-4159.1977.tb09621.x
pubmed: 886334
Perry TL, Hansen S, Kennedy J (1975) CSF amino acids and plasma–CSF amino acid ratios in adults. J Neurochem 24(3):587–589. https://doi.org/10.1111/j.1471-4159.1975.tb07680.x
doi: 10.1111/j.1471-4159.1975.tb07680.x
pubmed: 1113130
Heckel T, Broer A, Wiesinger H, Lang F, Broer S (2003) Asymmetry of glutamine transporters in cultured neural cells. Neurochem Int 43(4–5):289–298. https://doi.org/10.1016/s0197-0186(03)00014-7
doi: 10.1016/s0197-0186(03)00014-7
pubmed: 12742071
Leke R, Schousboe A (2016) The glutamine transporters and their role in the glutamate/GABA-glutamine cycle. Adv Neurobiol 13:223–257. https://doi.org/10.1007/978-3-319-45096-4_8
doi: 10.1007/978-3-319-45096-4_8
pubmed: 27885631
Albrecht J, Zielinska M (2019) Exchange-mode glutamine transport across CNS cell membranes. Neuropharmacology 161:107560. https://doi.org/10.1016/j.neuropharm.2019.03.003
doi: 10.1016/j.neuropharm.2019.03.003
pubmed: 30853601
Schioth HB, Roshanbin S, Hagglund MG, Fredriksson R (2013) Evolutionary origin of amino acid transporter families SLC32, SLC36 and SLC38 and physiological, pathological and therapeutic aspects. Mol Aspects Med 34(2–3):571–585. https://doi.org/10.1016/j.mam.2012.07.012
doi: 10.1016/j.mam.2012.07.012
pubmed: 23506890
Hellsten SV, Hagglund MG, Eriksson MM, Fredriksson R (2017) The neuronal and astrocytic protein SLC38A10 transports glutamine, glutamate, and aspartate, suggesting a role in neurotransmission. FEBS Open Bio 7(6):730–746. https://doi.org/10.1002/2211-5463.12219
doi: 10.1002/2211-5463.12219
pubmed: 28593130
pmcid: 5458457
Conway ME (2020) Alzheimer’s disease: targeting the glutamatergic system. Biogerontology 21(3):257–274. https://doi.org/10.1007/s10522-020-09860-4
doi: 10.1007/s10522-020-09860-4
pubmed: 32048098
pmcid: 7196085
Broer A, Wagner CA, Lang F, Broer S (2000) The heterodimeric amino acid transporter 4F2hc/y+LAT2 mediates arginine efflux in exchange with glutamine. Biochem J 349(Pt 3):787–795. https://doi.org/10.1042/bj3490787
doi: 10.1042/bj3490787
pubmed: 10903140
pmcid: 1221206
Lyck R, Ruderisch N, Moll AG, Steiner O, Cohen CD, Engelhardt B, Makrides V, Verrey F (2009) Culture-induced changes in blood-brain barrier transcriptome: implications for amino-acid transporters in vivo. J Cereb Blood Flow Metab 29(9):1491–1502. https://doi.org/10.1038/jcbfm.2009.72
doi: 10.1038/jcbfm.2009.72
pubmed: 19491922
Felipo V (2013) Hepatic encephalopathy: effects of liver failure on brain function. Nat Rev Neurosci 14(12):851–858. https://doi.org/10.1038/nrn3587
doi: 10.1038/nrn3587
pubmed: 24149188
Dabrowska K, Skowronska K, Popek M, Obara-Michlewska M, Albrecht J, Zielinska M (2018) Roles of glutamate and glutamine transport in ammonia neurotoxicity: state of the art and question marks. Endocr Metab Immune Disord Drug Targets 18(4):306–315. https://doi.org/10.2174/1871520618666171219124427
doi: 10.2174/1871520618666171219124427
pubmed: 29256360
Hermenegildo C, Monfort P, Felipo V (2000) Activation of N-methyl-D-aspartate receptors in rat brain in vivo following acute ammonia intoxication: characterization by in vivo brain microdialysis. Hepatology 31(3):709–715. https://doi.org/10.1002/hep.510310322
doi: 10.1002/hep.510310322
pubmed: 10706562
Skowronska M, Albrecht J (2013) Oxidative and nitrosative stress in ammonia neurotoxicity. Neurochem Int 62(5):731–737. https://doi.org/10.1016/j.neuint.2012.10.013
doi: 10.1016/j.neuint.2012.10.013
pubmed: 23142151
Llansola M, Rodrigo R, Monfort P, Montoliu C, Kosenko E, Cauli O, Piedrafita B, El Mlili N, Felipo V (2007) NMDA receptors in hyperammonemia and hepatic encephalopathy. Metab Brain Dis 22(3–4):321–335. https://doi.org/10.1007/s11011-007-9067-0
doi: 10.1007/s11011-007-9067-0
pubmed: 17701332
Hilgier W, Fresko I, Klemenska E, Beresewicz A, Oja SS, Saransaari P, Albrecht J, Zielinska M (2009) Glutamine inhibits ammonia-induced accumulation of cGMP in rat striatum limiting arginine supply for NO synthesis. Neurobiol Dis 35(1):75–81. https://doi.org/10.1016/j.nbd.2009.04.004
doi: 10.1016/j.nbd.2009.04.004
pubmed: 19379813
Zielinska M, Ruszkiewicz J, Hilgier W, Fresko I, Albrecht J (2011) Hyperammonemia increases the expression and activity of the glutamine/arginine transporter y+ LAT2 in rat cerebral cortex: implications for the nitric oxide/cGMP pathway. Neurochem Int 58(2):190–195. https://doi.org/10.1016/j.neuint.2010.11.015
doi: 10.1016/j.neuint.2010.11.015
pubmed: 21115085
Zielinska M, Skowronska M, Fresko I, Albrecht J (2012) Upregulation of the heteromeric y(+)LAT2 transporter contributes to ammonia-induced increase of arginine uptake in rat cerebral cortical astrocytes. Neurochem Int 61(4):531–535. https://doi.org/10.1016/j.neuint.2012.02.021
doi: 10.1016/j.neuint.2012.02.021
pubmed: 22401943
Zielinska M, Milewski K, Skowronska M, Gajos A, Zieminska E, Beresewicz A, Albrecht J (2015) Induction of inducible nitric oxide synthase expression in ammonia-exposed cultured astrocytes is coupled to increased arginine transport by upregulated y(+)LAT2 transporter. J Neurochem 135(6):1272–1281. https://doi.org/10.1111/jnc.13387
doi: 10.1111/jnc.13387
pubmed: 26448619
Bassi MT, Gasol E, Manzoni M, Pineda M, Riboni M, Martín R, Zorzano A, Borsani G, Palacín M (2001) Identification and characterisation of human xCT that co-expresses, with 4F2 heavy chain, the amino acid transport activity system xc-. Pflugers Arch 442(2):286–296. https://doi.org/10.1007/s004240100537
doi: 10.1007/s004240100537
pubmed: 11417227
Ottestad-Hansen S, Hu QX, Follin-Arbelet VV, Bentea E, Sato H, Massie A, Zhou Y, Danbolt NC (2018) The cystine-glutamate exchanger (xCT, Slc7a11) is expressed in significant concentrations in a subpopulation of astrocytes in the mouse brain. Glia 66(5):951–970. https://doi.org/10.1002/glia.23294
doi: 10.1002/glia.23294
pubmed: 29350434
Sato H, Shiiya A, Kimata M, Maebara K, Tamba M, Sakakura Y, Makino N, Sugiyama F, Yagami K, Moriguchi T, Takahashi S, Bannai S (2005) Redox imbalance in cystine/glutamate transporter-deficient mice. J Biol Chem 280(45):37423–37429. https://doi.org/10.1074/jbc.M506439200
doi: 10.1074/jbc.M506439200
pubmed: 16144837
Dixon SJ, Lemberg KM, Lamprecht MR, Skouta R, Zaitsev EM, Gleason CE, Patel DN, Bauer AJ, Cantley AM, Yang WS, Morrison B, Stockwell BR (2012) Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell 149(5):1060–1072. https://doi.org/10.1016/j.cell.2012.03.042
doi: 10.1016/j.cell.2012.03.042
pubmed: 22632970
pmcid: 3367386
Liu J, Xia X, Huang P (2020) xCT: A critical molecule that links cancer metabolism to redox signaling. Mol Ther. https://doi.org/10.1016/j.ymthe.2020.08.021
doi: 10.1016/j.ymthe.2020.08.021
pubmed: 33359791
pmcid: 7791083
Dai L, Noverr MC, Parsons C, Kaleeba JA, Qin Z (2015) xCT, not just an amino-acid transporter: a multi-functional regulator of microbial infection and associated diseases. Front Microbiol 6:120. https://doi.org/10.3389/fmicb.2015.00120
doi: 10.3389/fmicb.2015.00120
pubmed: 25745420
pmcid: 4333839
Hsieh CH, Lin YJ, Chen WL, Huang YC, Chang CW, Cheng FC, Liu RS, Shyu WC (2017) HIF-1α triggers long-lasting glutamate excitotoxicity via system xc− in cerebral ischaemia–reperfusion. J Pathol 241(3):337–349. https://doi.org/10.1002/path.4838
doi: 10.1002/path.4838
pubmed: 27801527
Merckx E, Albertini G, Paterka M, Jensen C, Albrecht P, Dietrich M, Van Liefferinge J, Bentea E, Verbruggen L, Demuyser T, Deneyer L, Lewerenz J, van Loo G, De Keyser J, Sato H, Maher P, Methner A, Massie A (2017) Absence of system x c- on immune cells invading the central nervous system alleviates experimental autoimmune encephalitis. J Neuroinflammation 14(1):9. https://doi.org/10.1186/s12974-016-0787-0
doi: 10.1186/s12974-016-0787-0
pubmed: 28086920
pmcid: 5237180
Fan Z, Wirth AK, Chen D, Wruck CJ, Rauh M, Buchfelder M, Savaskan N (2017) Nrf2-Keap1 pathway promotes cell proliferation and diminishes ferroptosis. Oncogenesis 6(8):e371. https://doi.org/10.1038/oncsis.2017.65
doi: 10.1038/oncsis.2017.65
pubmed: 28805788
pmcid: 5608917
Roh JL, Kim EH, Jang H, Shin D (2017) Aspirin plus sorafenib potentiates cisplatin cytotoxicity in resistant head and neck cancer cells through xCT inhibition. Free Radic Biol Med 104:1–9. https://doi.org/10.1016/j.freeradbiomed.2017.01.002
doi: 10.1016/j.freeradbiomed.2017.01.002
pubmed: 28057599
Wang SF, Chen MS, Chou YC, Ueng YF, Yin PH, Yeh TS, Lee HC (2016) Mitochondrial dysfunction enhances cisplatin resistance in human gastric cancer cells via the ROS-activated GCN2-eIF2α-ATF4-xCT pathway. Oncotarget 7(45):74132–74151. https://doi.org/10.18632/oncotarget.12356
doi: 10.18632/oncotarget.12356
pubmed: 27708226
pmcid: 5342041
Ishimoto T, Nagano O, Yae T, Tamada M, Motohara T, Oshima H, Oshima M, Ikeda T, Asaba R, Yagi H, Masuko T, Shimizu T, Ishikawa T, Kai K, Takahashi E, Imamura Y, Baba Y, Ohmura M, Suematsu M, Baba H, Saya H (2011) CD44 variant regulates redox status in cancer cells by stabilizing the xCT subunit of system xc(-) and thereby promotes tumor growth. Cancer Cell 19(3):387–400. https://doi.org/10.1016/j.ccr.2011.01.038
doi: 10.1016/j.ccr.2011.01.038
pubmed: 21397861
Ju HQ, Lu YX, Chen DL, Tian T, Mo HY, Wei XL, Liao JW, Wang F, Zeng ZL, Pelicano H, Aguilar M, Jia WH, Xu RH (2016) Redox regulation of stem-like cells though the CD44v-xCT axis in colorectal cancer: mechanisms and therapeutic implications. Theranostics 6(8):1160–1175. https://doi.org/10.7150/thno.14848
doi: 10.7150/thno.14848
pubmed: 27279909
pmcid: 4893643
Bolli E, O’Rourke JP, Conti L, Lanzardo S, Rolih V, Christen JM, Barutello G, Forni M, Pericle F, Cavallo F (2018) A virus-like-particle immunotherapy targeting epitope-specific anti-xCT expressed on cancer stem cell inhibits the progression of metastatic cancer. Oncoimmunology 7(3):e1408746. https://doi.org/10.1080/2162402X.2017.1408746
doi: 10.1080/2162402X.2017.1408746
pubmed: 29399412
Hilf N, Kuttruff-Coqui S, Frenzel K, Bukur V, Stevanović S, Gouttefangeas C, Platten M, Tabatabai G, Dutoit V, van der Burg SH, Thor Straten P, Martínez-Ricarte F, Ponsati B, Okada H, Lassen U, Admon A, Ottensmeier CH, Ulges A, Kreiter S, von Deimling A, Skardelly M, Migliorini D, Kroep JR, Idorn M, Rodon J, Piró J, Poulsen HS, Shraibman B, McCann K, Mendrzyk R, Löwer M, Stieglbauer M, Britten CM, Capper D, Welters MJP, Sahuquillo J, Kiesel K, Derhovanessian E, Rusch E, Bunse L, Song C, Heesch S, Wagner C, Kemmer-Brück A, Ludwig J, Castle JC, Schoor O, Tadmor AD, Green E, Fritsche J, Meyer M, Pawlowski N, Dorner S, Hoffgaard F, Rössler B, Maurer D, Weinschenk T, Reinhardt C, Huber C, Rammensee HG, Singh-Jasuja H, Sahin U, Dietrich PY, Wick W (2019) Actively personalized vaccination trial for newly diagnosed glioblastoma. Nature 565(7738):240–245. https://doi.org/10.1038/s41586-018-0810-y
doi: 10.1038/s41586-018-0810-y
pubmed: 30568303
Keskin DB, Anandappa AJ, Sun J, Tirosh I, Mathewson ND, Li S, Oliveira G, Giobbie-Hurder A, Felt K, Gjini E, Shukla SA, Hu Z, Li L, Le PM, Allesøe RL, Richman AR, Kowalczyk MS, Abdelrahman S, Geduldig JE, Charbonneau S, Pelton K, Iorgulescu JB, Elagina L, Zhang W, Olive O, McCluskey C, Olsen LR, Stevens J, Lane WJ, Salazar AM, Daley H, Wen PY, Chiocca EA, Harden M, Lennon NJ, Gabriel S, Getz G, Lander ES, Regev A, Ritz J, Neuberg D, Rodig SJ, Ligon KL, Suvà ML, Wucherpfennig KW, Hacohen N, Fritsch EF, Livak KJ, Ott PA, Wu CJ, Reardon DA (2019) Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial. Nature 565(7738):234–239. https://doi.org/10.1038/s41586-018-0792-9
doi: 10.1038/s41586-018-0792-9
pubmed: 30568305
Sontheimer H, Bridges RJ (2012) Sulfasalazine for brain cancer fits. Expert Opin Investig Drugs 21(5):575–578. https://doi.org/10.1517/13543784.2012.670634
doi: 10.1517/13543784.2012.670634
pubmed: 22404218
pmcid: 3644176
Robert SM, Buckingham SC, Campbell SL, Robel S, Holt KT, Ogunrinu-Babarinde T, Warren PP, White DM, Reid MA, Eschbacher JM, Berens ME, Lahti AC, Nabors LB, Sontheimer H (2015) SLC7A11 expression is associated with seizures and predicts poor survival in patients with malignant glioma. Sci Transl Med 7(289):286. https://doi.org/10.1126/scitranslmed.aaa8103
doi: 10.1126/scitranslmed.aaa8103
Sørensen MF, Heimisdóttir SB, Sørensen MD, Mellegaard CS, Wohlleben H, Kristensen BW, Beier CP (2018) High expression of cystine-glutamate antiporter xCT (SLC7A11) is an independent biomarker for epileptic seizures at diagnosis in glioma. J Neurooncol 138(1):49–53. https://doi.org/10.1007/s11060-018-2785-9
doi: 10.1007/s11060-018-2785-9
pubmed: 29404978
Savaskan NE, Heckel A, Hahnen E, Engelhorn T, Doerfler A, Ganslandt O, Nimsky C, Buchfelder M, Eyüpoglu IY (2008) Small interfering RNA-mediated xCT silencing in gliomas inhibits neurodegeneration and alleviates brain edema. Nat Med 14(6):629–632. https://doi.org/10.1038/nm1772
doi: 10.1038/nm1772
pubmed: 18469825
Chen L, Li X, Liu L, Yu B, Xue Y, Liu Y (2015) Erastin sensitizes glioblastoma cells to temozolomide by restraining xCT and cystathionine-γ-lyase function. Oncol Rep 33(3):1465–1474. https://doi.org/10.3892/or.2015.3712
doi: 10.3892/or.2015.3712
pubmed: 25585997
Sehm T, Rauh M, Wiendieck K, Buchfelder M, Eyüpoglu IY, Savaskan NE (2016) Temozolomide toxicity operates in a xCT/SLC7a11 dependent manner and is fostered by ferroptosis. Oncotarget 7(46):74630–74647. https://doi.org/10.18632/oncotarget.11858
doi: 10.18632/oncotarget.11858
pubmed: 27612422
pmcid: 5342691
Sleire L, Skeie BS, Netland IA, Førde HE, Dodoo E, Selheim F, Leiss L, Heggdal JI, Pedersen PH, Wang J, Enger P (2015) Drug repurposing: sulfasalazine sensitizes gliomas to gamma knife radiosurgery by blocking cystine uptake through system Xc-, leading to glutathione depletion. Oncogene 34(49):5951–5959. https://doi.org/10.1038/onc.2015.60
doi: 10.1038/onc.2015.60
pubmed: 25798841
Bauer AJ, Gieschler S, Lemberg KM, McDermott AE, Stockwell BR (2011) Functional model of metabolite gating by human voltage-dependent anion channel 2. Biochemistry 50(17):3408–3410. https://doi.org/10.1021/bi2003247
doi: 10.1021/bi2003247
pubmed: 21425834
Dixon SJ, Patel DN, Welsch M, Skouta R, Lee ED, Hayano M, Thomas AG, Gleason CE, Tatonetti NP, Slusher BS, Stockwell BR (2014) Pharmacological inhibition of cystine-glutamate exchange induces endoplasmic reticulum stress and ferroptosis. Elife 3:e02523. https://doi.org/10.7554/eLife.02523
doi: 10.7554/eLife.02523
pubmed: 24844246
pmcid: 4054777
Keating GM, Santoro A (2009) Sorafenib: a review of its use in advanced hepatocellular carcinoma. Drugs 69(2):223–240. https://doi.org/10.2165/00003495-200969020-00006
doi: 10.2165/00003495-200969020-00006
pubmed: 19228077
Shukla K, Thomas AG, Ferraris DV, Hin N, Sattler R, Alt J, Rojas C, Slusher BS, Tsukamoto T (2011) Inhibition of xc
doi: 10.1016/j.bmcl.2011.07.081
pubmed: 21889337
Patel SA, Rajale T, O’Brien E, Burkhart DJ, Nelson JK, Twamley B, Blumenfeld A, Szabon-Watola MI, Gerdes JM, Bridges RJ, Natale NR (2010) Isoxazole analogues bind the system xc- transporter: structure-activity relationship and pharmacophore model. Bioorg Med Chem 18(1):202–213. https://doi.org/10.1016/j.bmc.2009.11.001
doi: 10.1016/j.bmc.2009.11.001
pubmed: 19932968
Newell JL, Keyari CM, McDaniel SW, Diaz PJ, Natale NR, Patel SA, Bridges RJ (2014) Novel di-aryl-substituted isoxazoles act as noncompetitive inhibitors of the system Xc(-) cystine/glutamate exchanger. Neurochem Int 73:132–138. https://doi.org/10.1016/j.neuint.2013.11.012
doi: 10.1016/j.neuint.2013.11.012
pubmed: 24333322
Song X, Zhu S, Chen P, Hou W, Wen Q, Liu J, Xie Y, Klionsky DJ, Kroemer G, Lotze MT, Zeh HJ, Kang R, Tang D (2018) AMPK-mediated BECN1 phosphorylation promotes ferroptosis by directly blocking system X c- activity. Curr Biol 28(15):2388-2399.e2385. https://doi.org/10.1016/j.cub.2018.05.094
doi: 10.1016/j.cub.2018.05.094
pubmed: 30057310
pmcid: 6081251
Pineda M, Font M, Bassi MT, Manzoni M, Borsani G, Marigo V, Fernández E, Río RM, Purroy J, Zorzano A, Nunes V, Palacín M (2004) The amino acid transporter asc-1 is not involved in cystinuria. Kidney Int 66(4):1453–1464. https://doi.org/10.1111/j.1523-1755.2004.00908.x
doi: 10.1111/j.1523-1755.2004.00908.x
pubmed: 15458438
Nicoll RA (2017) A brief history of long-term potentiation. Neuron 93(2):281–290. https://doi.org/10.1016/j.neuron.2016.12.015
doi: 10.1016/j.neuron.2016.12.015
pubmed: 28103477
Hill MD, Goyal M, Menon BK, Nogueira RG, McTaggart RA, Demchuk AM, Poppe AY, Buck BH, Field TS, Dowlatshahi D, van Adel BA, Swartz RH, Shah RA, Sauvageau E, Zerna C, Ospel JM, Joshi M, Almekhlafi MA, Ryckborst KJ, Lowerison MW, Heard K, Garman D, Haussen D, Cutting SM, Coutts SB, Roy D, Rempel JL, Rohr ACR, Iancu D, Sahlas DJ, Yu AYX, Devlin TG, Hanel RA, Puetz V, Silver FL, Campbell BCV, Chapot R, Teitelbaum J, Mandzia JL, Kleinig TJ, Turkel-Parrella D, Heck D, Kelly ME, Bharatha A, Bang OY, Jadhav A, Gupta R, Frei DF, Tarpley JW, McDougall CG, Holmin S, Rha JH, Puri AS, Camden MC, Thomalla G, Choe H, Phillips SJ, Schindler JL, Thornton J, Nagel S, Heo JH, Sohn SI, Psychogios MN, Budzik RF, Starkman S, Martin CO, Burns PA, Murphy S, Lopez GA, English J, Tymianski M (2020) Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial. Lancet 395(10227):878–887. https://doi.org/10.1016/S0140-6736(20)30258-0
doi: 10.1016/S0140-6736(20)30258-0
pubmed: 32087818
Traynelis SF, Wollmuth LP, McBain CJ, Menniti FS, Vance KM, Ogden KK, Hansen KB, Yuan H, Myers SJ, Dingledine R (2010) Glutamate receptor ion channels: structure, regulation, and function. Pharmacol Rev 62(3):405–496. https://doi.org/10.1124/pr.109.002451
doi: 10.1124/pr.109.002451
pubmed: 20716669
pmcid: 2964903
Uno Y, Coyle JT (2019) Glutamate hypothesis in schizophrenia. Psychiatry Clin Neurosci 73(5):204–215. https://doi.org/10.1111/pcn.12823
doi: 10.1111/pcn.12823
pubmed: 30666759
Kaplan E, Zubedat S, Radzishevsky I, Valenta AC, Rechnitz O, Sason H, Sajrawi C, Bodner O, Konno K, Esaki K, Derdikman D, Yoshikawa T, Watanabe M, Kennedy RT, Billard JM, Avital A, Wolosker H (2018) ASCT1 (Slc1a4) transporter is a physiologic regulator of brain d-serine and neurodevelopment. Proc Natl Acad Sci U S A 115(38):9628–9633. https://doi.org/10.1073/pnas.1722677115
doi: 10.1073/pnas.1722677115
pubmed: 30185558
pmcid: 6156681
Helboe L, Egebjerg J, Møller M, Thomsen C (2003) Distribution and pharmacology of alanine-serine-cysteine transporter 1 (asc-1) in rodent brain. Eur J Neurosci 18(8):2227–2238. https://doi.org/10.1046/j.1460-9568.2003.02966.x
doi: 10.1046/j.1460-9568.2003.02966.x
pubmed: 14622183
Rosenberg D, Artoul S, Segal AC, Kolodney G, Radzishevsky I, Dikopoltsev E, Foltyn VN, Inoue R, Mori H, Billard JM, Wolosker H (2013) Neuronal D-serine and glycine release via the Asc-1 transporter regulates NMDA receptor-dependent synaptic activity. J Neurosci 33(8):3533–3544. https://doi.org/10.1523/JNEUROSCI.3836-12.2013
doi: 10.1523/JNEUROSCI.3836-12.2013
pubmed: 23426681
pmcid: 6619521
Sakimura K, Nakao K, Yoshikawa M, Suzuki M, Kimura H (2016) A novel Na(+) -Independent alanine-serine-cysteine transporter 1 inhibitor inhibits both influx and efflux of D-Serine. J Neurosci Res 94(10):888–895. https://doi.org/10.1002/jnr.23772
doi: 10.1002/jnr.23772
pubmed: 27302861
Sason H, Billard JM, Smith GP, Safory H, Neame S, Kaplan E, Rosenberg D, Zubedat S, Foltyn VN, Christoffersen CT, Bundgaard C, Thomsen C, Avital A, Christensen KV, Wolosker H (2017) Asc-1 transporter regulation of synaptic activity via the tonic release of d-serine in the forebrain. Cereb Cortex 27(2):1573–1587. https://doi.org/10.1093/cercor/bhv350
doi: 10.1093/cercor/bhv350
pubmed: 26796213
Safory H, Neame S, Shulman Y, Zubedat S, Radzishevsky I, Rosenberg D, Sason H, Engelender S, Avital A, Hülsmann S, Schiller J, Wolosker H (2015) The alanine-serine-cysteine-1 (Asc-1) transporter controls glycine levels in the brain and is required for glycinergic inhibitory transmission. EMBO Rep 16(5):590–598. https://doi.org/10.15252/embr.201439561
doi: 10.15252/embr.201439561
pubmed: 25755256
pmcid: 4428048
Stępnicki P, Kondej M, Kaczor AA (2018) Current concepts and treatments of schizophrenia. Molecules 23 (8). doi: https://doi.org/10.3390/molecules23082087
Ishiwata S, Ogata S, Umino A, Shiraku H, Ohashi Y, Kajii Y, Nishikawa T (2013) Increasing effects of S-methyl-L-cysteine on the extracellular D-serine concentrations in the rat medial frontal cortex. Amino Acids 44(5):1391–1395. https://doi.org/10.1007/s00726-013-1464-6
doi: 10.1007/s00726-013-1464-6
pubmed: 23417484
Chamorro Á, Dirnagl U, Urra X, Planas AM (2016) Neuroprotection in acute stroke: targeting excitotoxicity, oxidative and nitrosative stress, and inflammation. Lancet Neurol 15(8):869–881. https://doi.org/10.1016/S1474-4422(16)00114-9
doi: 10.1016/S1474-4422(16)00114-9
pubmed: 27180033
Brown JM, Hunihan L, Prack MM, Harden DG, Bronson J, Dzierba CD, Gentles RG, Hendricson A, Krause R, Macor JE, Westphal RS (2014) In vitro characterization of a small molecule inhibitor of the alanine serine cysteine transporter -1 (SLC7A10). J Neurochem 129(2):275–283. https://doi.org/10.1111/jnc.12618
doi: 10.1111/jnc.12618
pubmed: 24266811
Kutchukian PS, Warren L, Magliaro BC, Amoss A, Cassaday JA, O’Donnell G, Squadroni B, Zuck P, Pascarella D, Culberson JC, Cooke AJ, Hurzy D, Schlegel KS, Thomson F, Johnson EN, Uebele VN, Hermes JD, Parmentier-Batteur S, Finley M (2017) Iterative focused screening with biological fingerprints identifies selective Asc-1 inhibitors distinct from traditional high throughput screening. ACS Chem Biol 12(2):519–527. https://doi.org/10.1021/acschembio.6b00913
doi: 10.1021/acschembio.6b00913
pubmed: 28032990
Yanagida O, Kanai Y, Chairoungdua A, Kim DK, Segawa H, Nii T, Cha SH, Matsuo H, Fukushima J, Fukasawa Y, Tani Y, Taketani Y, Uchino H, Kim JY, Inatomi J, Okayasu I, Miyamoto K, Takeda E, Goya T, Endou H (2001) Human L-type amino acid transporter 1 (LAT1): characterization of function and expression in tumor cell lines. Biochim Biophys Acta 1514(2):291–302. https://doi.org/10.1016/s0005-2736(01)00384-4
doi: 10.1016/s0005-2736(01)00384-4
pubmed: 11557028
Huttunen J, Peltokangas S, Gynther M, Natunen T, Hiltunen M, Auriola S, Ruponen M, Vellonen KS, Huttunen KM (2019) L-type Amino acid Transporter 1 (LAT1/Lat1)-utilizing prodrugs can improve the delivery of drugs into neurons, astrocytes and microglia. Sci Rep 9(1):12860. https://doi.org/10.1038/s41598-019-49009-z
doi: 10.1038/s41598-019-49009-z
pubmed: 31492955
pmcid: 6731241
Wolosker H, Radzishevsky I (2013) The serine shuttle between glia and neurons: implications for neurotransmission and neurodegeneration. Biochem Soc Trans 41(6):1546–1550. https://doi.org/10.1042/BST20130220
doi: 10.1042/BST20130220
pubmed: 24256252